RNA binding by human Norovirus 3C-like proteases inhibits proteaseactivity  by Viswanathan, Prasanth et al.
Virology 438 (2013) 20–27Contents lists available at SciVerse ScienceDirectVirology0042-68
http://d
n Corr
E-mjournal homepage: www.elsevier.com/locate/yviroRNA binding by human Norovirus 3C-like proteases inhibits protease activityPrasanth Viswanathan, Jared May, Sunghae Uhm, Changsuek Yon, Brent Korba n
Georgetown University Medical Center, Department of Microbiology and Immunology, 3900 Reservoir Rd., N.W., Med-Dent Building, RM SW319, Washington,
DC 20057, United Statesa r t i c l e i n f o
Article history:
Received 15 October 2012
Returned to author for revisions
20 November 2012
Accepted 11 January 2013
Available online 9 February 2013
Keywords:
Norovirus
Protease
RNA binding22/$ - see front matter & 2013 Published by
x.doi.org/10.1016/j.virol.2013.01.006
esponding author. Fax: þ1 202 687 1800.
ail address: korbabe@georgetown.edu (B. Kora b s t r a c t
A highly active, ﬂuorescence-based, in vitro assay for human Norovirus protease from genogroup I and
II viruses was optimized utilizing as little as 0.25 mM enzyme, pH 7.6, and substrate:enzyme of 50–100.
Activity in Tris–HCl or sodium phosphate buffers was 2-fold less than HEPES, and 2-fold lower for
buffer concentrations over 10 mM. Protease activity at pH 7.6 was 73% (GI) or 63% (GII) of activity at the
optimal pH 9.0. Sodium inhibited activity 2–3 fold, while potassium, calcium, magnesium, and
manganese inhibited 5–10 fold. Differences in efﬁciency due to pH, buffer, and cations were due to
changes in kcat and not Km. Norovirus protease bound short RNAs representing the 30 or 50 ends of the
virus, inhibiting protease activity (IC50 3–5 mM) in a non-competitive manner. Previous reports
indicated participation of the protease in the Norovirus replicase complex. The current studies provide
initial support for a deﬁned role for the viral protease in Norovirus replication.
& 2013 Published by Elsevier Inc.Introduction
Noroviruses are a group of related non-enveloped, single-
stranded, positive sense RNA viruses that cause acute gastroen-
teritis in humans. Noroviruses are the most common cause of
epidemic gastroenteritis, responsible for at least 50% of all
gastroenteritis outbreaks worldwide, while 1 in 15 (21 million)
residents in the United States acquire these infections annually
(Hall et al., 2011; Scallan et al., 2011). An estimated 9.4 million
episodes of foodborne illness occur in the United States every year
and 5.5 million (58%) are caused by Noroviruses (Hall et al., 2011;
Scallan et al., 2011). Noroviruses belong to the genus Norovirus, of
the family Caliciviridae (Kapikian et al., 1997; Zheng et al., 2006).
At least ﬁve genogroups (GI–GV) of Noroviruses have been
recognized based on the amino acid identity in the capsid protein,
VP1, with the human Noroviruses belonging to groups GI, GII, and
GIV (Kapikian et al., 1997; Zheng et al., 2006). GII viruses have
emerged as the most prevalent cause of disease (Hall et al., 2011;
Scallan et al., 2011).
The prototype human Calicivirus, Norwalk Virus, has a 7.7 kb
positive sense single-stranded RNA genome that encodes three
open reading frames (ORFs) (Kapikian et al., 1997). ORF 1 encodes
a 200 KDa polyprotein, which is cleaved by the 3C-like cysteine
protease of the virus into six non-structural proteins necessary for
viral replication, one of which is the viral protease. The absolute
requirement of the protease of Noroviruses (NoV pro), makes it anElsevier Inc.
ba).attractive target for antiviral intervention (Blakeney et al., 2003;
Hardy et al., 2002; Tiew et al., 2011). A crystal structure of the
Norwalk virus 3C protease has been solved and mutational
analysis has identiﬁed the amino acids critical for activity
(Nakamura et al., 2005; Someya et al., 2008; Someya and
Takeda, 2011; Zeitler et al., 2006). A peptide mimic inhibitor of
the Southampton Norovirus 3C protease has been modeled into a
crystal structure that provides further insight into functional
residues (Zeitler et al., 2006).
We have developed a highly active ﬂuorescence-based in vitro
assay to quantitatively measure the activity of NoV pro for both
the GI and GII viruses that is notably more robust than most
previously reported assays (Belliot et al., 2003; Blakeney et al., 2003;
Chang et al., 2012; Hardy et al., 2002; Hussey et al., 2011; Schefﬂer
et al., 2007; Tiew et al., 2011; Someya et al., 2008: Someya and
Takeda, 2011; Zeitler et al., 2006). This assay operates in a 96-well
format with low enzyme concentrations, produces a high signal-to-
background ratio, is highly reproducible, and was used to character-
ize buffer, ion, and pH requirements of the protease, which have not
been systematically examined in previous reports. To provide a basis
for the mechanisms involved in the observed effect on activity, we
have determined that these components affect catalytic activity
(kcat), but not binding afﬁnity for the peptide substrate (Km).
Our examination of the published crystal structure of NoV pro
revealed a potential ATP binding motif. Since NoV pro is hypothe-
sized to directly participate in the viral replicase (Belliot et al.,
2005, 2008; Cancio-Lonches et al., 2011; Machı´n et al., 2009; Wei
et al., 2001), we investigated the interaction of RNA oligomers
representing the 30 and 50 ends of the viral genome and NTPs with
the viral protease. We provide the ﬁrst evidence for direct RNA
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inhibits protease activity. These observations provide initial
evidence for a deﬁned role of NoV pro in the viral replicase,
possibly similar to that observed for Rhinovirus and Poliovirus
(Andino et al., 1993; Hammerle et al., 1992; Leong et al., 1993;
Matthews et al., 1994).Fig. 1. Effect of pH and buffering agent on NoV pro activity. NoV pro concentration
was 0.5 mM and substrate was held at 100-fold excess for all conditions. Values
were determined at 60 min of reaction, and values for duplicate reactions are
presented. Panel A: Effect of pH. Data are presented as a percentage of the
maximum value. Assays were conducted in 50 mM Tris–HCl. Panel B: Effect of
buffering agent on GI pro. Buffering agents were used at 50 mM. Data are
presented (in duplicate at each point) as a percentage of the highest assay value
observed (HEPES, pH 8.0, set at 100). Bars denote standard deviations. Panel C:
Effect of buffer concentration. Assays were conducted at pH 7.6. Data are
presented as a percentage of the highest assay value observed (10 mM HEPES,
set at 100%). Bars denote standard deviations. Maximum net RLU (after back-
ground subtraction) for each panel were: A, 1642(GI), 2015(GII); B, 1693(GI);
C, 1439(GI).Results
Cations and buffer composition reduce NVpro activity
Nearly all previously published human Norovirus protease (NoV
pro) assays have utilized 50–100 mM sodium phosphate buffer,
pH 8.0 or greater, NaCl at 100–150 mM, enzyme concentrations of
2 mM or greater, and relatively low substrate:enzyme ratios (less
than 10) (Belliot et al., 2003; Blakeney et al., 2003; Chang et al.,
2012; Hardy et al., 2002; Hussey et al., 2011; Schefﬂer et al., 2007;
Tiew et al., 2011; Someya et al., 2008: Someya and Takeda, 2011;
Zeitler et al., 2006). However, there is little information on the
relative effect of alternative assay conditions, or a systematic
examination of reaction conditions and components. The standard
buffer composition for the NoV pro activity assay in the current
study (10 mM HEPES, pH 7.6, 0.1% CHAPS, 5 mM DTT, 30% glycerol)
was based on empirical observations that examined the effect of pH,
detergent, buffering agent, and commonly utilized cations.
Activity of NoV pro from both genogroup I (GI) and II (GII)
viruses was examined and was found to be essentially identical
overall. Protease activity was maximal at pH 8.6–9.0, but strong
protease activity at more physiologically relevant levels was
retained (Fig. 1A). At pH 7.6, the GI pro retained 73% and the GII
pro retained 63% of the activity at the optimal pH (Fig. 1A).
Protease activity in HEPES was at least 2-fold higher than in Tris–
HCl or NaPO4 across a range of pH values (Fig. 1B,C). Protease
activity at buffer concentrations higher than 10 mM was reduced
for all three buffering agents examined at pH 7.6 (Fig. 1C).
For the GI pro, NaCl inhibited activity 2-fold at approximately
90 mM, but higher concentrations up 300 mM had little addi-
tional effect (Fig. 2A). KCl, MgCl2, MgSO4, CaCl2, and MnCl2 were
more inhibitory, inducing a 2-fold reductions at as little as
5–10 mM in some instances, and up to 10-fold at higher concen-
trations (Fig. 2A,B). Relative to the GI protease, the GII enzyme
appeared to be slightly more sensitive to NaCl and MgCl2 and
slightly less sensitive to MgSO4 and CaCl2 (Fig. 2A,B). Data for
zinc is not included as addition at any concentration induced
precipitation.
While the addition of CHAPS and DTT only modestly enhanced
GI pro activity (with a greater apparent effect on GII pro at lower
concentrations) (Fig. 2C,D), DTT and CHAPS were included in the
ﬁnal reaction buffer to potentially aid solubility and stability of
the enzyme. EDTA at concentrations up to 0.5 mM, and DMSO at
concentrations of up to 5%, did not affect protease activity (data
not shown).
In the standard assay buffer, NoV pro concentrations as low as
0.25 mM consistently produced signals at least 2-fold higher than
background (no enzyme) control reactions (Fig. 3, top panel).
Enzyme concentrations of 0.5 mM and 1.0 mMwere much superior
to lower concentrations. Maximal efﬁciency of the reaction was
observed at a 100-fold excess of substrate relative to NoV pro
(Fig. 3, bottom panel).
NVpro binds RNA which inhibits protease activity
Previous studies have provided evidence that Norovirus and
other Calicivirus proteases participate in the viral replicase com-
plex either as the mature cleaved protein (pro) or the un-cleavedprecursor protein (propol) (Belliot et al., 2005, 2008; Cancio-
Lonches et al., 2011; Machı´n et al., 2009; Wei et al., 2001) but
no distinct role for protease in this complex has been demon-
strated. Our examination of the amino acid sequence and three
dimensional structure of NoV pro (SitePredict
TM
, http://sitepredict.
org) indicated the presence of a potential ATP binding pocket
deﬁned by the following amino acids: M107, I109, Q110, R112,
V114, S118, L121, G133, T134, I135, P136, G137, D138, C139,
H157, A158, A159, A160, T161, K162, S163, G164, N165, T166,
V167, V168. The effects of NTPs on protease activity were
subsequently examined. All four NTPs appeared to weakly inhibit
GI pro activity (IC50 1.2–2.9 mM), but did not inhibit activity
substantially further at increasing concentrations up to 10 mM
Fig. 2. Effect of cations and assay components NoV pro activity. NoV pro concentration was 0.5 mM and substrate was held at 100-fold excess for all conditions. Reactions
were conducted in 10 mM HEPES, pH 7.6. Values were determined at 60 min of reaction. Data are presented (in duplicate at each point) as a percentage of the highest assay
value observed (set at 100%) for each variable. Maximum net RLU (after background subtraction) for each panel were: A, 1721(GI), 1421(GII); B, 1335(GI), 1607 (GII);
C, 1552(GI), 1582 (GII); D, 1678 (GI), 1359 (GII).
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interaction overall.
RNA oligonucleotides (14-mer) representing both polarities of
the 30 and 50 ends of the viral genome were also examined for
interactions with NoV pro. In contrast to the NTPs, all RNA
oligonucleotides efﬁciently inhibited the activity of the GI pro in
a dose responsive manner at 1000-fold lower concentrations (IC50
3.5–5.5 mM), reducing activity 10-fold or more at 20–25 mM
(Table 1, Fig. 4A). The GII pro was similarly inhibited by the
presence of the RNA oligomer representing the anti-genomic
polarity 50 end (50RS) at the same concentration range (IC50,
6.970.4 mM), demonstrating that this is likely a general feature
of the human Norovirus proteases. The Ki for the 5
0RS oligomer
with the GI pro was 5.270.3 mM.
To determine if more natural RNAs inhibited the NoV protease,
a 600nt RNA encoding for GI pro from pET32NVpro3C-1 was
utilized. This RNA inhibited GI pro activity substantially more
efﬁciently, and at more physiologically relevant concentrations,
than the 14-mer oligonucleotides (Table 1). To determine if this
RNA represented evidence for sequence preference, a 660nt RNA
initiated from the from the same T7 promoter in the pET-32a
vector was used. This non-NoV related, plasmid RNA inhibited GI
pro with equal efﬁciency (Table 1), indicating that length, not
sequence, was responsible for the more potent inhibition. GII pro
was also inhibited by the 658nt GI pro RNA at the same low
concentration range (IC50, 2270.5 nM; IC90, 6271.6 nM), as was
GII propol (IC50, 9.371.0 nM; IC90, 29.572.1 nM).NoV pro directly binds RNA
Incubation of the GI pro with the 32P-labelled 50RS RNA
oligomer induced a migration shift in acrylamide gel electrophor-
esis (Fig. 5). This is the ﬁrst evidence presented for RNA binding
by a human Norovirus protease. RNA binding by other viral 3C
proteases, such as Rhinovirus and Poliovirus, is well established
(Andino et al., 1993; Hammerle et al., 1992; Leong et al., 1993;
Matthews et al., 1994).RNA and cations affected the rate of reaction but not afﬁnity for the
peptide substrate
To provide a basis for potential mechanisms responsible for
observed differences in protease activity in the presence of RNA
and under various assay conditions, enzyme kinetics and para-
meters for NoV pro were determined. Overall, Km and kcat for the
GI and GII proteases were essentially identical under the standard
assay conditions (Table 2, Fig. 6A). The presence of 5.0 mM RNA
(50 sense oligonucleotide) did not signiﬁcantly affect the relative
afﬁnity of the GI pro for the peptide substrate (Km) (p40.1), but
reduced the relative rate of reaction (kcat) over 2-fold, consistent
with a pattern of non-competitive inhibition (Table 2, Fig. 6D).
Differences in the relative activity of the GI pro under different
assay conditions also appeared to be due to changes in kcat and
not alterations of Km (Table 2, Fig. 6B). For the GI pro, kcat was
3-fold greater in Tris buffer at pH 8.8 than at pH 7.6, resulting in a
3-fold increase in enzymatic efﬁciency. At pH 7.6, kcat was 2-fold
higher in HEPES relative to Tris–HCl, for the GI pro, resulting in
more than a 2-fold increase in reaction efﬁciency. The reasons for
these differences are currently unclear. The effects of pH may
potentially be due to differences in overall charge of the GI and GII
enzymes (GI pI¼7.87, GII pI¼8.74) and/or overall charge of the
substrate (3.2 at pH 7.6 vs. 4.0 at pH 8.8) (Protein CalculatorTM,
v3.3, www.scripps.edu).
The effects of two cations at concentrations that reduced
protease activity approximately 2-fold were also studied. In
HEPES, pH 7.6, the presence of 100 mM NaCl or 10 mM MgCl2
did not affect Km signiﬁcantly, but reduced kcat and enzymatic
efﬁciency signiﬁcantly (Table 2, Fig. 6C).Discussion
In this report, we present the ﬁrst evidence of direct binding of
RNA by human Norovirus proteases. Furthermore, the binding of
RNA by these viral enzymes inhibits protease activity in a dose
responsive manner. While NTPs also appeared to inhibit protease
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Fig. 3. Effect of enzyme and substrate concentration on NoV pro activity. Protease assays were conducted in standard assay buffer as described in the methods section.
Data for triplicate reactions at each time point are presented. Comparisons of different enzyme concentrations (top panel) were performed at a constant enzyme:substrate
ratio of 1:100. Comparisons of enzyme:substrate ratios (bottom panel) were conducted using 1.0 mM enzyme.
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that observed for several RNA oligomers, and the lack of dose
response beyond 2-fold inhibition indicates a relatively weak,
non-speciﬁc interaction overall.
RNA binding by other viral 3C proteases, such as the Poliovirus
and Rhinovirus proteases, is well established (Andino et al., 1993;
Hammerle et al., 1992; Leong et al., 1993; Matthews et al., 1994).
Unlike that observed for the Picornavirus proteases, there currently
appears to be little evidence for RNA sequence speciﬁcity for the
Norovirus enzymes, although RNA length appears to play an
important role in the interaction. These issues need to be further
investigated. Norovirus and other Calicivirus proteases have been
implicated as being a crucial part of the viral replicase (Belliot et al.,
2005, 2008; Cancio-Lonches et al., 2011; Machı´n et al., 2009; Wei
et al., 2001) but, no distinct role for the protease in this complex has
been demonstrated. Our data provides initial evidence for a distinct
role, possibly similar to that observed for the Poliovirus and
Rhinovirus proteases in template recognition (Andino et al., 1993;
Hammerle et al., 1992; Leong et al., 1993; Matthews et al., 1994).
Unlike that observed for the human Norovirus proteases in our
studies, RNA binding by the Poliovirus and Rhinovirus proteasesdoes not affect protease activity, presumably due to RNA binding
sites that are distant and well-displaced from the catalytic site
(Andino et al., 1993; Hammerle et al., 1992; Leong et al., 1993;
Matthews et al., 1994). The amino acids involved with RNA
binding by NoV pro have yet to be determined and are the subject
of ongoing investigations in our laboratory. It is possible that, for
Noroviruses, the RNA binding motif overlaps, or is adjacent to, the
catalytic site, which would explain the observed inhibition.
However, the non-competitive pattern of the inhibition of pro-
tease activity by RNA is more consistent with adjacent binding
motifs. Previous studies have suggested that the un-cleaved
precursor protein (propol) composed of the Norovirus protease
and polymerase is active in the viral replicase since it possesses
both protease and polymerase activity (Belliot et al., 2005, 2008;
Cancio-Lonches et al., 2011; Machı´n et al., 2009; Wei et al., 2001).
In this case, inhibition of viral protease activity to prevent the
self-cleavage of propol under ionic conditions that favor Norovirus
polymerase activity, such as the presence of magnesium, sodium,
as well as the presence of RNA, would be favorable to the virus.
The systematic investigation of assay and enzyme storage
conditions, which has not been previously reported for the human
Table 1
Potency of RNA oligomers and NTPs against NoV protease activity.
IC50 (mM) IC90 (mM)
Oligonucleotides (14-mer)
50-End, sense 5.570.1 23.371.1
50-End antisense 4.870.5 18.671.2
30-End, sense 5.470.1 21.570.2
30-End antisense 3.570.2n 10.770.9nn
Nucleotides
ATP 1500791 –a
UTP 1252749 –a
CTP 29007416nnn –a
GTP 1752723 –a
RNAs
NoV pro (642nt) 0.01370.001 0.04670.003
pET32 (589nt) 0.01770.002 0.06270.002
NTPs or RNAs were pre-incubated with GI pro in standard assay buffer for 15 min.
Substrate was then added and the reaction incubated for an additional 30 min at
37 1C as described in the methods section. IC50 (2-fold reduction of NoV pro
activity relative to control) and IC90 (10-fold reduction of NoV pro activity relative
to control) values (7 standard deviations) were calculated by linear regression
analysis (MS Excel). For the longer length RNAs, ‘NoV pro’ speciﬁes the RNA
encoding the GI pro gene in pET32NVpro3C-1, and ‘pET32’ speciﬁes non-NoV RNA
from the parent vector, pET32.
n po0.01 (t test) vs. other nucleotides.
nn po0.001 (t test) vs. other nucleotides.
nnn po0.03 (t test) vs. other NTPs.
a IC90 not calculated due to lack of sufﬁcient inhibition (see Fig. 3).
Fig. 4. Effect of RNA and NTPs on NoV pro activity. Oligonucleotides and NTP’s
were pre-incubated with GI pro in standard assay buffer for 15 min as described in
the methods section. Data are presented as a percentage of the control (1% DMSO)
reaction (set at 100%). Maximum net RLU (after background subtraction) for each
panel were A, 2298; B, 1960.
Fig. 5. RNA binding by NoV pro. Products were electrophoresed on a 12% non-
denaturing PAGE gel. Incubations with GI pro and 32P-labelled RNA (14-mer,
50 end, genomic polarity) were in standard assay buffer at 37 1C for 15 min prior to
electrophoresis. For each lane, 20 pM 32P-labelled RNA was used with the
indicated amount of NoV pro. RNA was radio-labeled using T4 polynucleotide
kinase (New England Biolabs) according to the manufacturer’s instructions.
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Norovirus protease assays reported to date (Belliot et al., 2003;
Blakeney et al., 2003; Chang et al., 2012; Hardy et al., 2002;
Hussey et al., 2011; Schefﬂer et al., 2007; Tiew et al., 2011;
Someya et al., 2008: Someya and Takeda, 2011; Zeitler et al.,
2006). Importantly, the optimization of assay conditions in this
report allows for the efﬁcient conduct of studies with this
important viral enzyme to be conducted at a more physiologic
pH (7.2–7.6) than those previously used (8.0–9.0).
Most previous NoV pro assays utilized conditions which we
have demonstrated to be suboptimal or inhibitory. In previous
assays, this has necessitated the use of 5- to 20-fold more enzyme
per reaction, and much smaller substrate to enzyme ratios (0.1–10),
the latter of which we have shown limits assay dynamic range. Most
previous assays used reaction buffers containing 50 mM sodium
phosphate (or Tris–HCl) with 100–150 mMNaCl, and enzyme stored
in 10–30% glycerol in the presence of 100–150 mM NaCl in sodium
phosphate buffer. We attribute the increased activity of the current
assay to the (i) use of higher (50%) glycerol concentrations, HEPES,
and the lack of cations for enzyme storage, (ii) the absence of cations
in the reaction buffer, (iii) lower concentrations of buffering agent,
and (iv) the use of HEPES instead of sodium phosphate or Tris–HCl
as the buffering agent.
In our studies, cations, pH, and buffer composition affected the
relative rate of reaction (kcat), but not afﬁnity for the peptide
substrate (Km). Similarly, the presence of RNA did not affect
substrate binding substantially but reduced the rate of reaction,
consistent with a pattern of non-competitive inhibition.
The basis for the increased activity in the current investiga-
tions may be attributed to the signiﬁcant improvement in Km. For
example, kcat values in our studies at pH 7.6 were comparable to
those observed at pH 8.0 for a human GI pro in a recent report
(Chang et al., 2012), but Km values in our studies were approxi-
mately 40-fold lower, resulting in a proportionately greater
efﬁciency of reaction (kcat/Km). The kcat values in our studies at
pH 7.6 were 2- to 6-fold less than those observed for a South-
ampton virus protease (a GI Norovirus) at pH 8.5 (Zeitler et al.,
2006), but Km values in our studies were 16- to 80-fold lower.
Table 2
Kinetic analysis of NoV pro activity.
Enzyme Km (mM) kcat (s1)(103) kcat/Km (M1 s1)
10 mM HEPES, pH 7.6 GI 18.3770.82 5.270.10 283
10 mM HEPES, pH 7.6 GII 23.1172.35nn 5.170.20 224
10 mM Tris–HCl, pH 7.6 GI 20.3372.71 2.370.10n 113
10 mM Tris–HCl, pH 8.8 GI 31.0572.09 6.570.11n,nn 209
10 mM HEPES, pH 7.6þ10 mM MgCl2 GI 22.7471.71 0.970.01n 40
10 mM HEPES, pH 7.6þ100 mM NaCl GI 26.6572.95 2.070.10n 75
10 mM HEPES, pH 7.6þ5 uM RNA GI 20.6672.86 2.770.10n 101
Analysis was performed in triplicate.
n po0.001 (two-tailed t test, GraphPadTM, GraphPad Software, Inc.) vs. 10 mM HEPES, pH 7.6.
nn po0.001 (two-tailed t test vs. 10 mM Tris–HCl, pH 7.6). Km values were not statistically different (p40.05).
Fig. 6. Kinetics of NoV pro reaction. Reactions (average values from triplicate analyses) are displayed for GI pro comparing (Panel A) GI pro and GII pro in standard assay
buffer (panel B) HEPES vs. Tris–HCl at pH 7.6, (panel C) effect of NaCl and MgCl2. Panel D: Lineweaver-Burk analysis of the effect of RNA (14-mer, 5
0 end, genomic polarity)
on GI pro activity. All graphs were created with GraphPad
TM
.
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We present in this paper a well-characterized, highly active,
assay for the analysis of protease activity of human Norovirus 3-C
like proteases. Enzymatic efﬁciency of proteases from both a GI
and GII virus were essentially identical. We have, for the ﬁrst
time, systematically characterized the buffer component require-
ments for these enzymes, and determined that these components
affect catalytic activity (kcat), but not binding afﬁnity for the
peptide substrate (Km) which provides a basis for exploring the
mechanisms related to these effects. We also present the ﬁrst
demonstration of RNA binding by a human Norovirus protease,
providing a basis for a potential deﬁnitive role for its participation
in the viral replicase, perhaps similar to that observed for the
Rhinovirus and Poliovirus proteases. RNA binding inhibits Nor-
ovirus protease activity, distinguishing this interaction from that
observed in Picornavirus 3C proteases.Experimental procedures
Construction of the expression vectors
A clone, pETSumoNVpro (strain Hu/GI.1/8FIIa/1968/USA,
accession number JX023285), obtained from K.O. Chang (Kansas
State University, USA), was used as the source material for the GI
protease. The NoV protease (NoV pro) gene was ampliﬁed from
pETsumoNVpro using the forward primer NdeNVp (5-TCAT-
CAAAGCTT CATTCTAGTGCGGTTTCGCCCTC-30) and the reverse
primer HindNVp (50-TCATCAAAGCTTCAT TCTAGTGCGGTTTCG-
CCCTC-30). NdeNVp introduced an NdeI site and a hexahistidine
tag into the 50 end of the amplicon. HindNVp introduced a stop
codon after the NVprotease reading frame, a HindIII site, and six
additional nucleotides to the 30 end of the amplicon. To facilitate
efﬁcient restriction digestion of the 50NdeI site, an additional six
nucleotides were added to the 50 end by re-amplifying the
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CATCA CCATCACC-30) and HindNVp. Both the pET-32a vector
and the full length NVpro amplicon were digested with NdeI
and HindIII, puriﬁed, and ligated to form the pET32NVpro3C-1
expression construct.
The GII NoV pro gene was cloned from the cDNA clone pGEMT-
Easy-NV41 (strain Hu/GII.4/ Ast6139/01/Sp, accession number
AJ583672), provided by F. Parra (Universidad de Oviedo, Spain)
using the forward primer NV3C-F (50-TGCATCACCATCACCAT-
CACGCCCCACCAAGCATC TGGTC-30) and the reverse primer
NV3C-R (50-GCAGAATTCTCATTCA AGTGTAGCCTCCCCCT-30). The
forward primer contained a hexahistidine tag along with a 50-TG
di-nucleotide that formed a start codon after ligation into the
end-ﬁlled NdeI site in the vector. The pET-32a vector was digested
with NdeI and ﬁlled in with Pfu DNA polymerase to form a blunt
end, and subsequently digested with EcoRI. The cloned NVpro
fragment was digested with EcoRI and ligated into the pET-32a
vector to form the pET32NVpro3C-2 expression construct. For
both NVpro constructs, DH5a Escherichia coli were transformed
and selected for with 100 mg/ml ampicillin.
The GII NoV propol gene was cloned from the same plasmid
(provided by F. Parra) into the same vector, and using the same
strategy used for the GII protease gene using the forward primer
NV3C-F (50-TGCATCACCATCACCATCACGCCCCACCAAGCATCTG-
GTC-30) and the reverse primer NVRp-R (50-GCAGAATTCTCATT
CGACGCCATCTTCATTCA-30) to form the pET32NVpropol3C-2
expression construct. Clones from resistant colonies for all con-
structs were sequenced to ensure successful insertion and
orientation.
Protein expression and puriﬁcation
Expression and puriﬁcation of NoV proteases was performed
following previously described procedures (Yon et al., 2011).
Brieﬂy, E. coli BL21 Star (DE3) cells transformed with the indivi-
dual protease expression constructs were grown at 37 1C in
750 ml of Luria broth containing 100 mg/ml ampicillin. Protein
expression was induced with IPTG. Cells were harvested, lysed by
sonication, centrifuged, and the supernatant incubated with Talon
metal afﬁnity resin (Clontech Laboratories, Inc.). The resin was
then washed, and the fusion protein was eluted with imidazole.
Eluted fractions were checked for purity by SDS-PAGE and
quantiﬁed by spectrophotometry.
Fractions of highest concentrations were pooled and dialyzed
against storage buffer (10 mM HEPES, pH 7.6, 50% glycerol, 5 mM
DTT), and aliquots were stored at either 4 1C or 20 1C. Enzyme
yield was at least 20 mg/750 ml culture and was pure (495%) of
other detectable proteins following analysis in SDS-PAGE. Studies
on the storage of NoV pro demonstrated that the presence of 50%
glycerol is required for long term stability (data not shown).
Currently, enzyme activity upon storage is stable for at least
4 weeks at 4 1C and at least 12 months at 20 1C or 70 1C.
Norovirus protease assay
The protease assay depends on the sequence-speciﬁc cleavage
of the 14 amino acid FRET peptide substrate, Edans-EPDFHLQG-
PEDLAK-Dabcyl, between Q and G (Hardy et al., 2002) by active
NoV protease and the subsequent detection of ﬂuorescence. The
substrate was custom synthesized commercially (New England
peptide, Inc.). The standard assay reaction consists of 10 mM
HEPES (pH 7.6), 0.1% CHAPS, 10 mM DTT, 30% glycerol, 0.5–1.0 mM
NVpro enzyme and 25–100 mM substrate peptide (50–100:1 relative
to NVpro). On addition of the substrate, the reaction was incubated at
37 1C., and ﬂuorescence was measured at excitation and emissionmaxima of 360 and 460 nm respectively in a SPECTRAmaxs GEMINI-
EM Fluorescence microplate reader (Molecular Devices Inc.).
Analysis of enzyme parameters
Kinetic analysis of the enzyme was performed in 1X assay
buffer (10 mM HEPES, pH:7.6, 0.1% CHAPS, 10 mM DTT, 30%
glycerol) using 1.0 mM enzyme and 3.9–125 mM substrate pep-
tide. Fluorescence formed over 20 min was monitored at 1.0 min
intervals at 37 1C. Measured ﬂuorescence was converted to
products formed in mM, using a standard curve of free EDANS.
Km and kcat were determined by non-linear regression analysis
using Prism
TM
software (v5.0a, Graphpad Software Inc.).
For this report, RNA was considered to be an inhibitor of NoV
proteases, not a substrate. To determine the dissociation constant
(Ki) of RNA oligonucleotides, Km and kcat analysis of NVpro was
carried out in presence of 0, 1.25, 2.5 and 5.0 mM 5’RS RNA. Ki was
determined by non-linear curve ﬁt into non-competitive mode of
inhibition using Prism software. Changes in kinetic parameters of
the enzyme under differing pH and buffer conditions were
analyzed in 10 mM Tris–HCl, 0.1% CHAPS, 10 mM DTT, and 30%
Glycerol at pH 7.6 and 8.8. Statistical analysis of enzyme para-
meters was assessed by two-tailed t test (GraphPad
TM
, GraphPad
Software, Inc).
Transcription and puriﬁcation of RNAs
The HPLC-puriﬁed, 14-mer RNA oligonucleotides used for this
study were manufactured by IDT, Inc. A 642nt RNA encoding the GI
pro gene was transcribed from the T7 promoter of pET32NVpro3C-1
(linearized with HindIII). A non-NoV related, 589nt RNA was
transcribed from the T7 promoter of the parent vector, pET32
(linearized with HindIII). Both RNAs were produced using the
MEGAscript T7 kit (Life Technologies, Inc.) following the manufac-
turer’s instructions. Transcription reaction products were extracted
twice by phenol:chloroform:Isoamyl alcohol (1:1:1), precipitated
with 0.3 mM sodium acetate, pH 5.5 and ethanol, the pellets washed
twice with 70% ethanol to remove salts, re-suspended in RNase-free
water (Ambion, Inc.), and stored at 70 1C.
Gel shift RNA binding studies
RNA (14-mer, 50 end, genomic polarity) was 32P-labeled using T4
polynucleotide kinase (New England Biolabs, Inc.) according to the
manufacturer’s instructions. For each reaction, 20 pM 32P-labelled
RNA was incubated with different amounts of NoV GI pro in
standard assay buffer at 37 1C for 15 min prior to electrophoresis.
The reactions were then immediately subjected to electrophoresis
on a 12% non-denaturing PAGE gel in TBE buffer.Acknowledgments
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